Omega Therapeutics, Inc. OMGA
We take great care to ensure that the data presented and summarized in this overview for Omega Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OMGA
View all-
Flagship Pioneering Inc. Cambridge, MA29.2MShares$6.72 Million6.56% of portfolio
-
Harbourvest Partners LLC Boston, MA3.51MShares$807,7852.79% of portfolio
-
State Of Wisconsin Investment Board Madison, WI1.86MShares$427,1700.0% of portfolio
-
Siren, L.L.C. New York, NY1.32MShares$304,4110.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.1MShares$252,3340.0% of portfolio
-
Chi Advisors LLC New York, NY1.06MShares$242,8521.12% of portfolio
-
Blue Owl Capital Holdings LP New York, NY1.06MShares$242,8520.34% of portfolio
-
683 Capital Management, LLC New York, NY600KShares$138,0000.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny521KShares$119,8060.0% of portfolio
-
Black Rock Inc. New York, NY364KShares$83,7090.0% of portfolio
Latest Institutional Activity in OMGA
Top Purchases
Top Sells
About OMGA
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at OMGA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 02
2023
|
Richard A Young |
SELL
Open market or private sale
|
Direct |
5,000
-0.67%
|
$40,000
$8.0 P/Share
|
|
May 01
2023
|
Richard A Young |
SELL
Open market or private sale
|
Direct |
5,000
-0.67%
|
$40,000
$8.0 P/Share
|
|
Apr 06
2023
|
Richard A Young |
SELL
Open market or private sale
|
Direct |
5,000
-0.66%
|
$40,000
$8.0 P/Share
|
|
Mar 17
2023
|
Richard A Young |
SELL
Open market or private sale
|
Direct |
10,000
-1.31%
|
$80,000
$8.0 P/Share
|
|
Feb 27
2023
|
Flagship Pioneering Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,323,310
+35.49%
|
$16,616,550
$5.78 P/Share
|
|
Jan 10
2023
|
Richard A Young |
SELL
Open market or private sale
|
Direct |
20,000
-2.55%
|
$160,000
$8.0 P/Share
|
|
Sep 14
2022
|
Richard A Young |
SELL
Open market or private sale
|
Direct |
10,000
-1.26%
|
$80,000
$8.0 P/Share
|
|
Feb 01
2022
|
Mahesh Karande President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,300
+8.76%
|
$0
$0.53 P/Share
|
|
Aug 03
2021
|
Flagship Pioneering Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,352,938
+9.53%
|
$39,999,946
$17.0 P/Share
|
|
Aug 03
2021
|
Flagship Pioneering Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
45,057,482
+50.0%
|
-
|
|
Aug 03
2021
|
David A Berry Director |
BUY
Open market or private purchase
|
Direct |
53,082
+50.0%
|
$902,394
$17.0 P/Share
|
|
Aug 03
2021
|
Roger Sawhney Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,941
+50.0%
|
$49,997
$17.0 P/Share
|
|
Aug 03
2021
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
875,000
+27.79%
|
$14,875,000
$17.0 P/Share
|
|
Aug 03
2021
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,323,530
+48.62%
|
-
|
|
Jul 30
2021
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
75,000
+50.0%
|
$1,200,000
$16.14 P/Share
|